Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06HNO
|
||||
Former ID |
DIB001673
|
||||
Drug Name |
MEDI4920
|
||||
Indication | Sjogren's syndrome [ICD9: 710.2; ICD10:M35.0] | Phase 1 | [524779] | ||
Target and Pathway | |||||
Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | Inhibitor | [524779], [531635] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
NF-kappa B signaling pathway | |||||
Cell adhesion molecules (CAMs) | |||||
T cell receptor signaling pathway | |||||
Intestinal immune network for IgA production | |||||
Malaria | |||||
Toxoplasmosis | |||||
Asthma | |||||
Autoimmune thyroid disease | |||||
Systemic lupus erythematosus | |||||
Allograft rejection | |||||
Primary immunodeficiency | |||||
Viral myocarditis | |||||
References | |||||
Ref 524779 | ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health. | ||||
Ref 531635 | Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.